TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Rodríguez Sanz, Maria, 1984-ca
• dc.contributor.author Pineda-Moncusí, Martaca
• dc.contributor.author Servitja Tormo, Soniaca
• dc.contributor.author Garcia Giralt, Natàliaca
• dc.contributor.author Martos, Tamaraca
• dc.contributor.author Tusquets Trias de Bes, Ignacioca
• dc.contributor.author Martínez-García, Mariaca
• dc.contributor.author Rodriguez-Morera, Jaimeca
• dc.contributor.author Díez Pérez, Adolfoca
• dc.contributor.author Albanell Mestres, Joanca
• dc.contributor.author Nogués Solan, Francesc Xavierca
• dc.date.accessioned 2017-02-02T08:24:24Z
• dc.date.issued 2016
• dc.description.abstract INTRODUCTION: Patients with breast cancer under aromatase inhibitor (AI) treatment often develop osteoporosis and their average bone loss rate is twice that of natural reduction during menopause, increasing fracture risk. As the current diagnostic technique based on bone mineral density (BMD) provides no information on bone quality, the Trabecular Bone Score (TBS) has been proposed to reflect bone microarchitecture status. The present study was designed to assess prospective changes in TBS and lumbar spine (LS) BMD in postmenopausal women with breast cancer at completion of AI treatment. METHODS: B-ABLE is a prospective cohort of 735 women with breast cancer treated with AIs according to American Society of Clinical Oncology recommendations: 5years of AI starting within 6weeks post-surgery or 1month after the last cycle of chemotherapy (5y-AI group), or switching to an AI to complete 5-year therapy after 2-3years of tamoxifen (pTMX-AI group). Patients with osteoporosis were treated with oral bisphosphonates (BP). TBS and LS-BMD changes at completion of AI therapy were evaluated by Student t-test for paired samples. Pearson correlation coefficients were computed for correlations between LS-BMD and TBS. RESULTS: AI treatment was completed by 277 women. Of these, 70 (25.3%) were allocated to BP therapy. The non-BP-treated patients (74.7%) showed significant decreases in TBS (-2.94% in pTMX-AI and -2.93% in 5y-AI groups) and in LS-BMD (-4.14% in pTMX-AI and -2.28% in 5y-AI groups) at the end of AI treatment. In BP-treated patients, TBS remained stable at the end of AI treatment, whereas LS-BMD showed significant increases (+2.30% in pTMX-AI and +5.33% in 5y-AI groups). Moderate associations between TBS and LS-BMD values at baseline and at the end of AI treatment (r=0.4; P<0.001) were observed. At the end of treatment, changes in spine BMD and TBS were weakly correlated (r=0.1, P<0.01). CONCLUSIONS: AI therapy induces significant decreases in TBS, comparable to BMD loss. BP-treated patients maintained TBS values, whereas BMD increased. AI treatment leads to deterioration of bone microarchitecture, which seems to be attenuated by BP therapy.ca
• dc.description.sponsorship This work was supported by the Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad (RETICEF; RD12/0043/0022), and the Grant FIS PI10/01464 and PI13/00444 (Carlos III Health Institute, Science and Innovation Ministry); Grants from the Generalitat de Catalunya (DIUE 2014 SGR 775) and FEDER funds have supported this study.
• dc.format.mimetype application/pdfca
• dc.identifier.citation Rodríguez-Sanz M, Pineda-Moncusí M, Servitja S, Garcia-Giralt N ,Martos T, Tusquets I. et al. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort. Bone. 2016 Nov;92:1-8. doi: 10.1016/j.bone.2016.08.008ca
• dc.identifier.doi http://dx.doi.org/10.1016/j.bone.2016.08.008
• dc.identifier.issn 1873-2763
• dc.identifier.uri http://hdl.handle.net/10230/28032
• dc.language.iso engca
• dc.publisher Elsevierca
• dc.relation.ispartof Bone. 2016 Nov;92:1-8
• dc.rights © Elsevier http://dx.doi.org/10.1016/j.bone.2016.08.008ca
• dc.rights.accessRights info:eu-repo/semantics/openAccessca
• dc.subject.other Ossos -- Malaltiesca
• dc.subject.other Mama -- Càncerca
• dc.title TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.ca
• dc.type info:eu-repo/semantics/articleca
• dc.type.version info:eu-repo/semantics/acceptedVersionca